Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of a single dose (2
inhalations, 180 mcg total) of Albuterol SPIROMAX (90 mcg per inhalation) versus placebo in
patients with EIB.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries